Viracta Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Viracta Therapeutics

06/08/2021 23:03

* Viracta Therapeutics Inc  VIRX.OQ   VIRX.O  is expected
to show a no change in quarterly revenue when it reports
results on August 9 (estimated). 
​* Refinitiv's mean analyst estimate for Viracta Therapeutics
Inc is for a loss of 24 cents per share. For the same quarter
last year, the company reported a loss of $2.10 per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $35​, about 67.9% above​ its last closing
price of $11.25. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  0.03        -0.21      0.35      Beat    266.7
 Dec. 31 2020  -0.96       -0.96      -0.73     Beat    23.6
 Sep. 30 2020  -1.21       -1.18      -1.01     Beat    13.9​
 Jun. 30 2020  -1.87       -1.94      -2.10     Missed  -8.1
 Mar.          -2.41​      -2.44      -1.75     Beat    28.3​
 31​ 2020​                                              
 Dec. 31 2019  -2.64       -2.58      -1.75     Beat    32.2​
 Sep. 30 2019  -3.17       -2.97      -2.10     Beat    29.4
 Jun. 30 2019  -3.61       -3.47      -3.15     Beat    9.3
 This summary was machine generated August 6 at 22:03 GMT.  All
figures in US dollars unless otherwise stated